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Abstract
Background: Descurainia sophia seeds have a variety of pharmacological functions and been widely used in
traditional folk medicine. However, their effects on human drug metabolizing enzyme (DME) activities have not
been elucidated. The present study investigated the inhibitory effects of an ethanol extract of D. sophia seeds
(EEDS) on human Phase I/II (DMEs) and P-glycoprotein (p-gp) in vitro.
Methods: The enzyme activities of human Phase I (cytochrome P450s, CYPs), Phase II (uridine diphosphate
glucuronosyltransferases, UGTs) DMEs, and the drug transporter P-gp were determined in the presence of various
concentrations of EEDS using commercially available luminogenic assay systems. The mode of enzyme inhibition
and the inhibitory constant (Ki) value of EEDS were graphically determined with Lineweaver-Burk double reciprocal
plots and secondary plots, respectively.
Results: The enzyme activity assays showed that EEDS moderately inhibited the CYP1A2, CYP2C9, and CYP2C19
isoforms with half maximal inhibitory concentrations (IC50) of 47.3, 25.8, and 38.7 μg/mL, respectively. Graphical
analyses with Lineweaver-Burk double reciprocal plots and secondary plots indicated that EEDS competitively
inhibited CYP2C9 with a Ki value of 19.8 μg/mL; however, it inhibited CYP2C9 and CYP2C19 in a mixed mode with
Ki values of 5.2, and 11.9 μg/mL, respectively. Other Phase I (CYP2C8, CYP2D6, and CYP3A4) and Phase II (UGT1A1
and UGT2B7) enzymes as well as P-gp were weakly or negligibly affected by EEDS with concentrations up to
500 μg/mL.
Conclusions: EEDS is a selective inhibitor of CYP1A2, CYP2C9, and CYP2C19 with moderate enzymatic inhibition.
Clinically, full consideration should be given to a potential toxic adverse effect from a herb-drug interaction when
drugs that are particularly susceptible to CYP1A2, CYP2C9, or CYP2C19-mediated metabolism are taken together
with EEDS. Characterization of metabolic profiles of specific herbal drugs could help consumers and medical
specialists to use them safely as a complementary and alternative medicine.
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Background
In the past few decades, complementary and alternative
medicine (CAM) has been combined with conventional
medicine to treat diverse diseases. Approximately 38 % of
American adults (83 million) are using some form of
CAM for their healthcare, and their expenditures on
CAM reached $34 billion in 2007 [1]. In Eastern Asia, the
prevalence of CAM is much higher, and 76 % of Japanese
[2] and 93 % of Chinese cancer patients have used CAM
[3]. The proportion of population using CAM in the
Republic of Korea was reported as 75 % [4]. In addition,
herbal medicines are classified and regulated as formal
drugs in these Eastern Asian countries [5].
Herbal medicines comprise an important part of CAM
and are used worldwide. Consumers of herbal medicines
consider them safe and sometimes forget the fact that
herbal extracts contain many phytochemicals and that
they can act as substrates, inhibitors, or inducers modulat-
ing human metabolic enzymes [6]. The increasing practice
of co-administering herbal medicines with conventionally
prescribed medications has raised considerably the risk of
potential drug-herb interactions, especially in patients
who already are on complex treatments involving narrow
therapeutic index drugs [1, 7, 8]. Pharmacokinetic herb-
drug interactions are one of the major risks caused by
phytochemicals modulating the activities of enzymes that
metabolize drugs, which subsequently affects their bio-
availability [9]. For example, St. John's wort can decrease
the steady state plasma concentrations of cyclosporine,
midazolam, tacrolimus, amitriptyline, digoxin, indinavir,
warfarin, phenprocoumon, and theophylline [10]. Ginkgo
could enhance the hydroxylation of omeprazole by
CYP2C19 in a genotype-dependent manner, and garlic
could increase the EC50 of warfarin in wild-type vitamin K
epoxide reductase complex subunit 1 (VKORC1) in
patients [1]. The whole extract of kava, a well-known herbal
anxiolytic, can inhibit human CYP1A2, CYP2C9,
CYP2C19, CYP2D6, and CYP3A4 in vitro [11] and increase
the area under the concentration-time curve (AUC) and
the maximum achieved plasma concentration (Cmax) of co-
administered kawain in vivo [12]. These studies show that
determining the effects of individual herbal drugs on hu-
man drug metabolizing enzymes (DMEs) is important to
predict possible interactions with drugs which can poten-
tially be co-administered in clinics and to reduce the risk of
adverse side effects from their concomitant use. Therefore,
there is no doubt that chronic users of herbal medications,
which are known to inhibit or induce potent human DME
activities, should be aware of the potential adverse side
effects from herb-drug interactions as well as be carefully
advised by medical specialists before their use.
Descurainia sophia (L.) Webb ex Prantl (Flixweed),
which belongs to the family Brassicaceae (Cruciferae),
originates from Southern Europe and North Africa, and is
widely distributed in Northeastern China [13]. The ethno-
pharmacological uses of D. sophia seeds are to relieve
coughing and asthma, treat jaundice, reduce edema, pro-
mote urination, etc. [14]. A recent randomized clinical trial
showed that the oral administration of D. sophia seeds re-
lieved chronic functional constipation in children which
was statistically significant [15]. Some research groups in-
cluding us have identified various types of secondary me-
tabolites from D. sophia seeds. They are cardiac glycosides,
sinapoyl glycosides, flavonoids, lactones, lipids, coumarins,
nor-lignans, lignans, and phytosterols [14, 16–21]. The bio-
logical activities of some of the isolated phytochemicals are
anti-asthmatic, anti-tussive, expectorant [13], and anti-
inflammatory as well as cytotoxic activities against human
cancer cells [21]. Our previous genome-wide expression
analysis showed that the solid fraction of the ethanol extract
of D. sophia seeds regulated diverse genes which are closely
associated with several biological functions like cell survival
and death [22].
As evidence for the ethnopharmacological use of D.
sophia seeds increases, the clinical applications and me-
dicinal requirements of D. sophia seeds may increase
gradually. However, no scientific study is currently avail-
able showing the effects of D. sophia seeds on the activ-
ities of human DMEs. The goal of the present study was
to elucidate the inhibitory effect of D. sophia seeds on
major human DMEs including Phase I (cytochrome
P450s, CYPs) and Phase II (uridine diphosphate glucuro-
nosyltransferases, UGTs) enzymes and a drug trans-
porter (P-glycoprotein, P-gp).
Methods
Plant materials and extract preparation
The dried seeds of D. sophia were purchased from Kwang-
myungdang Medicinal Herbs Co. (Ulsan, Republic of
Korea). D. sophia seeds were collected in the Shandong
Province, China in June 2010 which was written on the
batch label. They were identified by Dr. Go Ya Choi at the
K-herb Research Center, Korea Institute of Oriental Medi-
cine, Daejeon, Republic of Korea. A voucher specimen
(KIOM-CRC-5) was deposited at the KM-Convergence
Research Division, Korea Institute of Oriental Medicine.
Whole extract of the dried seeds of D. sophia was pre-
pared by repeated maceration in 80 % (v/v) ethanol. The
solid phase of the ethanol extract (EEDS) was further con-
centrated and dried. Finally, the EEDS was stored at 4 °C.
The EEDS was dissolved in 100 % dimethylsulfoxide
(DMSO, Sigma, St Louis, MO, USA) to make a stock solu-
tion and then stored at -80 °C until used. A detailed pro-
cedure on preparing EEDS was described previously [22].
Luminogenic DME inhibition assays in vitro
In vitro enzymatic inhibition assays of human Phase I
(CYPs) and Phase II (UGTs) DME, and P-gp were done
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with commercially available luminogenic assay systems.
The assay systems were purchased from Promega
(Madison, WI, USA), and the microsomes containing
the recombinant human CYPs were purchased from
Life Technologies (Carlsbad, CA, USA). The micro-
somes containing human UGT and P-gp were supplied
in the luminogenic assay systems (Promega). The de-
tails on the assay systems and the microsomes are pre-
sented in Table 1. The activity for each enzyme was
determined in the presence and absence of serially
diluted EEDS. A known specific enzyme inhibitor was
included as a positive control to verify the validity of
each assay system. They are also summarized in Table 1.
The maximum tolerable concentration of the vehicle
(DMSO) was adjusted to 0.25 % (v/v) for all enzyme ac-
tivity assays except for the DMSO-sensitive CYP2C8
(0.05 %). The enzyme reaction was done according to
the manufacturer’s instructions. The luminescent inten-
sity, which is correlated with the enzyme activity, was
quantified with a TriStar LB 941 multimode microplate
reader (Berthold Technologies, Bad Wildbad, Germany).
The modulated enzyme activity by EEDS was evaluated
by comparing the changes in activity from the treatment
with the solvent alone to those from the treatment with
the EEDS. The apparent half-maximal inhibitory con-
centration (IC50) was determined with the SigmaPlot
program (version 11.0, Systat Software, Inc, San Jose,
CA, USA) with a 4-parameter logistic equation.
Determination of the modes of enzyme inhibition and the
inhibitory constant (Ki) values
The modes of enzyme inhibition and the Ki values were
further determined for the enzymes with IC50 values
less than 100 μg/mL. They were determined by incu-
bating a series of EEDS concentrations and different
concentrations of respective substrates for each enzyme
using the luminescence-based method described earlier.
The enzyme reaction conditions are summarized in
Table 2. The mode of enzyme inhibition was graphically
determined from the Lineweaver-Burk double reciprocal
plots. The Ki value was calculated with the secondary plot
representing the slope rate of the Lineweaver-Burk plot
versus the EEDS concentrations (0, 12.5, 25, 50, and
100 μg/mL) [23].
Statistics
The data are presented as the means ± standard devi-
ation (S.D.) for at least duplicate experiments. The
means and S.D. were determined with the SigmaPlot
program.
Results
Inhibitory effects of EEDS on human DME activities
The inhibitory effect of EEDS on human DME activities
were evaluated with the in vitro luminescent assay de-
scribed earlier. The calculated IC50 of the EEDS and spe-
cific inhibitors against each DME are presented in Table 3.
The inhibitory potencies of the test drugs were classified
as potent (IC50 ≤ 20 μg/mL for crude extract or IC50 ≤
10 μM for a single compound), moderate (20 < IC50 <
100 μg/mL or 10 < IC50 < 50 μM), or weak (IC50 ≥ 100 μg/
mL or IC50 ≥ 50 μM) [24]. According to this categorization,
the EEDS exhibited a moderate inhibitory effect on the
CYP1A2, CYP2C9, and CYP2C19 activities with an IC50 of
47.3, 25.8, and 38.7 μg/mL, respectively. However, CYP2C8
(IC50 > 100 μg/mL), CYP2D6 (IC50 = 137.5 μg/mL), and
3A4 (IC50 = 134.2 μg/mL) were weakly inhibited by EEDS.
The effect of EEDS on UGT1A1 was very weak (IC50 =
335.1 μg/mL) and on UGT2B7 and P-gp negligible
(IC50 > 500 μg/mL).
Determining the mode of enzyme inhibition and the Ki
value
Next, we determined the Ki values and the mode of
enzyme inhibition for the CYP1A2, CYP2C9, and
CYP2C19 isoforms with an IC50 less than 100 μg/mL for
Table 1 Summary of assay systems for human Phase I/II DME and P-gp inhibition assays
Types DMEs Assay kits Microsomes Specific inhibitors
Suppliers Cat # Suppliers Cat # Chemicals Suppliers Codes
Ph I CYP1A2 Promega V8772 Invitrogen P2792 α-naphthoflavone Sigma-Aldrich N5757
CYP2C8 Promega V8782 Invitrogen PV6138 Montelukast Cayman 10008318
CYP2C9 Promega V8792 Invitrogen P2378 Sulfaphenazole Sigma-Aldrich S0758
CYP2C19 Promega V8882 Invitrogen P2864 Ticlopidine Sigma-Aldrich T6654
CYP2D6 Promega V8892 Invitrogen P2283 Quinidine Sigma-Aldrich Q3625
CYP3A4 Promega V8802 Invitrogen P2858 Ketoconazole Sigma-Aldrich K1003
Ph II UGT1A1 Promega V2120 Microsome supplied in assay kit Diclofenac Sigma-Aldrich D6899
UGT2B7 Promega V2130 Microsome supplied in assay kit Diclofenac Sigma-Aldrich D6899
Drug transport P-gp Promega V3601 Microsome supplied in assay kit Na3VO4 supplied in assay kit
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the EEDS. From the results, the EEDS competitively
inhibited CYP2C9 but showed mixed inhibition for
CYP1A2 and CYP2C19 seen in the Lineweaver-Burk
double reciprocal plots (Fig. 1). The calculated Ki values
for CYP1A2, CYP2C9, and CYP2C19 were 19.8, 5.2, and
11.9 μg/mL, respectively (Fig. 1). Therefore, the most
potent inhibition by the EEDS was for CYP2C9 followed
by CYP2C19 and CYP1A2.
Discussion
The effect of a potential drug candidate on human
DMEs, such as the induction or inhibition of CYPs, can
be a safety issue because it can change the metabolism
of other co-administered xenobiotics or drugs uninten-
tionally, and subsequently enhance or reduce their
pharmacological or toxic profiles [25, 26]. In vitro en-
zymatic studies of human cytochrome P450 modulated
by a specific compound are considered cost-effective in
predicting the potential drug-drug interaction in clinical
trials [27]. In this study, we evaluated the modulation of
human DME and P-gp activities in vitro with ethanol ex-
tracts of D. sophia seeds. D. sophia seeds have been pre-
scribed as a folk medicine worldwide to treat or relieve
diverse diseases and symptoms, especially in eastern
Asian countries. D. sophia seeds have been traditionally
used as a component of herbal prescriptions. They have
been taken as a water extract after decoction or a round
pill just after grinding them. Therefore, taking into con-
sideration the conventional intake methods, we used re-
peated maceration in 80 % ethanol to extract the active
ingredients as much as possible.
In our previous study, we reported on the anticancer
effects of EEDS against various human cancer cell lines
and identified various bioactive constituents from EEDS
[21, 22]. Fourteen compounds were isolated from the
ethanol extract of D. sophia seeds by chromatographic
separation methods. Among them, helveticoside showed
the most potent cytotoxicity with an IC50 ranging from
0.034 to 0.596 μM depending on the human cancer cell
line. Quercetin and syringaresinol exerted dose-dependent
inhibitory effects on NO production in LPS-stimulated
RAW264.7 cells with median effective doses (ED50) of
5.5 μM and 10.0 μM, respectively. Several research groups
have reported on the biological activities of D. sophia
seeds. Khodarahmi et al. evaluated the cytotoxic effects of
volatile oil from D. sophia seeds on the MCF-7 and HeLa
cell lines with an IC50 of 70 μg/mL and 180 μg/mL, re-
spectively [28]. Gong et al. reported on the in vivo anti-
asthmatic, anti-tussive, and expectorant activities of D.
sophia seed oil supporting the ethnopharmacological use
of D. sophia seeds to relieve respiratory diseases [13]. To
the best of our knowledge, the present study is the first to
report the effect of the whole extract of D. sophia seeds
on human DMEs and P-gp. Biochemical luminogenic in-
hibition assays showed that human CYP1A2, CYP2C9,
and CYP2C19 were moderately inhibited by EEDS based
on their pharmacokinetic parameters (IC50 and Ki). Other
tested CYP isotypes including CYP2C8, CYP2D6, and
CYP3A4, were weakly inhibited by EEDS. These results
show that the bioavailability of drugs, which are metabolic
substrates of CYP1A2, CYP2C9, or CYP2C19, can be af-
fected when these drugs are concomitantly administered
with EEDS, causing potential adverse effects by elevating
Table 2 Summary of reaction conditions to determine modes
of CYP enzyme inhibition and Ki values
Parameters CYP1A2 CYP2C9 CYP2C19
Substrate (μM) Luciferin-ME Luciferin-H Luciferin-H EGE
(12.5 ~ 100) (25 ~ 200) (2.5 ~ 20)
Enzyme (pmol) 0.5 0.5 0.25
EEDS (μg/mL) 0-100 0-100 0-100
Incubation time (min) 10 30 20
Temperature (°C) 37 37 37
Luciferin-ME luciferin 6-methyl ether, Luciferin-H 6-deoxyluciferin, Luciferin-H
EGE ethylene glycol ester of 6-deoxyluciferin
Table 3 IC50 of EEDS on human DMEs
Types DMEs Inhibitors IC50
a
EEDS (μg/mL) Inhibitors (μM)
Ph I CYP1A2 α-naphthoflavone 47.3 ± 7.0 0.22 ± 0.03
CYP2C8 Montelukast >100 0.31 ± 0.02
CYP2C9 Sulfaphenazole 25.8 ± 1.9 0.13 ± 0.01
CYP2C19 Ticlopidine 38.7 ± 2.5 0.39 ± 0.03
CYP2D6 Quinidine 137.5 ± 0.3 0.08 ± 0.00
CYP3A4 Ketoconazole 134.2 ± 3.5 0.25 ± 0.03
Ph II UGT1A1 Diclofenac 335.1 ± 57.3 180.3 ± 29.6
UGT2B7 Diclofenac >500 179.4 ± 30.9
Drug transport P-gp Na3VO4 >500 3.40 ± 0.32
aValues are expressed as the means ± S.D. of at least duplicated experiments
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Fig. 1 Left panel, primary Lineweaver-Burk plots for CYP1A2, CYP2C9, and CYP2C19. The modes of enzyme inhibition were determined by incubating
an enzyme with a combination of different concentrations of EEDS and increasing the concentrations of specific substrates. Right panel, secondary
plots for CYP1A2, CYP2C9, and CYP2C19. Ki value was calculated by the secondary plot representing the slope rate of the Lineweaver-Burk plot versus
increasing the concentrations of EEDS. Minus Ki values (-Ki) from the plot intersect on the x-axis
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the plasma levels of cytotoxic drugs, or leading to
therapeutic failure by inhibiting the metabolic process-
ing of inactive prodrugs. Among approved drugs, the
substrates for CYP1A2 include amitriptyline (anti-de-
pression) and erlotinib (anticancer). The substrates for
CYP2C9 include ibuprofen (analgesic), warfarin (anti-
coagulant), and tamoxifen (anticancer). The substrates
for CYP2C19 include diazepam, mephenytoin (anti-epilep-
tic), methadone (analgesic) and bortezomib (anticancer)
(DrugBank, www.drugbank.ca) [6]. Many nonsteroidal anti-
inflammatory drugs (NSAID) are a substrate for CYP2C9.
If D. sophia seeds as an herbal formulation and a NSAID
like celecoxib, diclofenac, ibuprofen, or naproxen are co-
administered to treat cold, the two drugs will compete with
each other to bind with CYP2C9 [29, 30]. The decoction of
D. sophia seeds has been used as an antipyretic for measles
and smallpox [18], and to treat respiratory diseases in Korea
(DongUiBoGam, a classic medical book on Koran medi-
cine). If a patient is taking a drug for bronchitis, it is neces-
sary to consider the drug interactions between the anti-
inflammatory drugs of NSAIDs and the herbal formulation
of D. sophia seeds. For more information of cytochrome
P450 drug interactions, please refer to the following site
(http://medicine.iupui.edu/clinpharm/ddis/).
Due to the fact that CYP3A4 metabolizes more than
50 % of the clinically prescribed drugs and represents
the major metabolic enzyme in the human liver (40 %)
and intestinal mucosa (80 %), CYP3A4 could contribute
significantly to the metabolism of herbal drugs because
most of the herbal drugs including EEDS are orally ad-
ministered and metabolized primarily by the drug me-
tabolizing enzymes in the liver and intestinal mucosa
[6, 31, 32]. If EEDS is developed as a new anticancer
herbal drug, EEDS could possibly be taken together with
other conventional anticancer drugs. In our assay system,
CYP3A4 was weakly inhibited by EEDS with an IC50 of
134 μg/mL. Therefore, EEDS may only slightly affect the
bioavailability of anticancer drugs, such as dasatinib for
chronic myelogenous leukemia and gefitinib for locally ad-
vanced or metastatic non-small cell lung cancer (Drug-
Bank, www.drugbank.ca), whose primary administration
route is oral. These drugs are metabolized and eliminated
mainly by CYP3A4.
Graphical analysis with the Lineweaver-Bulk and sec-
ondary plots showed that the effect of EEDS on CYP2C9
is a competitive-type of inhibition. On the other hand, the
effects of EEDS on CYP1A2 and CYP2C19 were best fit-
ted to a mixed-type of inhibition. Competitive inhibition
of EEDS implies that EEDS competes with a substrate
(Luciferin-H used in this study) to bind to the active site
of CYP2C9. Therefore, the inhibition of CYP2C9 by EEDS
can be overcome by increasing the substrate concentra-
tion. The competitive inhibition of CYP is reversible
which is most commonly observed in both in vitro and
clinical settings [27]. In a non-competitive-type of inhib-
ition, both the inhibitor and substrate can bind to the en-
zyme at the same time because they have separate binding
sites on the enzyme, and therefore, the substrate or inhibi-
tor does not affect the binding of the other to the enzyme.
The mixed inhibition observed in CYP1A2 and CYP2C19
by EEDS is reversible and similar to noncompetitive inhib-
ition except that the binding of the substrate (Luciferin-
ME for CYP1A2 or Luciferin-H EGE for CYP2C19 in this
study) affects the binding of the inhibitor (EEDS) vice and
versa.
UGTs catalyze the glucuronidation reaction through
which the glucuronic acid moiety of UDP-glucuronic
acid is transferred to substrates or xenobiotics, which
are eliminated from the human body [33]. Although
UGTs are responsible for catalyzing approximately 35 %
of the drugs metabolized by Phase II enzymes and also in-
volved in the metabolism of several important endogenous
substances such as bilirubin, steroid hormones, thyroid
hormones, bile acid, and fat-soluble vitamins [34], the ef-
fect of herbal medicines on UGTactivity has not been well
characterized. Some phytochemicals isolated from Chin-
ese herbal medicines are known to inhibit UGTs. For ex-
ample, deoxyschizandrin and schisantherin A isolated
from Fructus schisandrae, which has been used as a tonic
in traditional Chinese medicine, potently inhibit the
UGT1A3 isotype [35]. In the present study, we evaluated
the inhibitory effect of EEDS on the UGT1A1 and
UGT2B7 isotypes. From the results, EEDS was found to
affect very weakly UGT1A1 (IC50 = 335.1 μg/mL) and
UGT2B7 (IC50 > 500 μg/mL) in our biochemical assay sys-
tem; thus, its effects on these two UST isotypes were
negligible.
The P-gp protein is an ATP-dependent drug efflux
transporter and also known as multidrug resistance 1
(MDR1) or ATB-binding cassette subfamily B member 1
(ABCB1). When the distribution of P-gp was determined
with a monoclonal antibody raised against P-gp, the distri-
bution of human P-gp in normal tissues was concentrated
in cells found in the intestinal epithelium, liver, proximal
tubule of the kidney, and capillary endothelium, where it
pumps back toxic materials into the intestinal lumen, bile
and urinary ducts, and capillaries, respectively [36–38].
Many studies reported that P-gp can interact with
herbal decoctions or extracts and with phytochemicals
isolated from medicinal herbs [36, 37, 39–41]. Admin-
istration of herbal medicines that affect P-gp activity
can induce enhanced drug toxicity or improve intra-
cellular drug transport by inhibiting the P-gp medi-
ated drug efflux. In the present study, however, EEDS
did not modulate the verapamil-stimulated ATPase
activity of P-gp up to the maximum concentration of
EEDS (500 μg/mL) tested in our biochemical assay
system.
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Some constituents of D. sophia seeds were evaluated for
their effects on human DMEs. Quercetin, a flavonoid, is a
potent competitive inhibitor of CYP1A2, CYP2C, CYP2C19
and CYP3A4 (Ki = 0.93, 1.67, 1.74 and 4.12 μM, respect-
ively) [42], and inhibits human UGT2B17, a key steroid–
metabolizing enzyme [43]. Additionally, Choi et al reported
that enhanced doxorubicin absorption in the gastrointes-
tinal tract is attributed to quercetin-induced inhibition of
P-gp and that the reduced first-pass metabolism of doxo-
rubicin is attributed to quercetin-induced inhibition of
CYP3A in the small intestine [44]. Syringaresinol, another
constituent of D. sophia, exhibited inhibitory effects on
P-gp in adriamycin-resisitant human breast cancer cells,
MCF-7/ADR [45].
Conclusions
In vitro enzyme activity assays showed that EEDS modu-
lates the activities of human Phase I/II DMEs and P-gp
to varying degrees of potency indicating the potential
risk of herb-drug interactions. CYP2C9 was competi-
tively inhibited; however, CYP1A2 and CYP2C19 were
inhibited in a mixed manner by EEDS with Ki values of
19.8, 5.2, and 11.9 μg/mL, respectively. CYP2C8, CYP2D6,
CYP3A4, UGT1A1, UGT2B7, and P-gp were not weakly
or negligibly affected by EEDS. In the present study, how-
ever, the bioactive constituent(s) responsible for affecting
the enzyme activities were not identified. Further studies
will have to be done to identify the responsible phyto-
chemical constituents and their enzyme modulating
properties. In addition, we should keep in mind that
various in vivo factors could influence in vitro to in vivo
extrapolation.
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